Organogenesis Holdings Inc.
ORGO evidence brief
What we can confirm
- Market Cap:
- $196.9M
What it means
What to watch
Prepared research question
What matters most for ORGO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ORGO
Organogenesis Holdings Inc. (ORGO) is a regenerative medicine company focused on advanced wound care and surgical/sports medicine, with a portfolio of FDA-cleared products and a pending BLA for its ReNu knee osteoarthritis treatment.
Key risk: Large net loss
Market Cap
$196.9M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Organogenesis Holdings Inc. (ORGO) is a regenerative medicine company focused on advanced wound care and surgical/sports medicine, with a portfolio of FDA-cleared products and a pending BLA for its ReNu knee osteoarthritis treatment.
- Cash & equivalents of $46.1M as of 2026-06-30 [sec].
- Total revenue of $43.8M and net loss of -$96.3M as of 2026-06-30 [sec].
- Shareholders' equity of $148.3M as of 2026-06-30 [sec].
- FDA accepted BLA for ReNu for knee osteoarthritis; PDUFA target action date set for April 24, 2027 [news].
- Company expects cash on hand plus product sales to fund operations for at least 12 months beyond August 2026 [sec_mda].
What works
- FDA acceptance of ReNu BLA with a PDUFA date of April 24, 2027, provides a clear regulatory catalyst [news].
- Company holds multiple FDA PMA or 510(k) clearances, which it views as a competitive advantage [sec_mda].
- Cash and working capital of $139.7M as of June 30, 2026, are expected to sustain operations for at least 12 months [sec_mda].
What to weigh
- Net loss of -$96.3M as of 2026-06-30 indicates significant ongoing operating losses [sec].
- Credit facility expired on August 6, 2026, removing a source of liquidity [sec_mda].
- ReNu BLA is not yet approved; regulatory and commercial risks remain until the PDUFA date [news].
From the filings
Quoted directly from source documents.
FDA accepted ReNu BLA with PDUFA date of April 24, 2027
“PDUFA Target Action Date Set for April 24, 2027”
News · July 6, 2026
Cash and equivalents of $46.1M as of June 30, 2026
“As of June 30, 2026, we had working capital of $139.7 million, which included $46.1 million in cash and cash equivalents.”
SEC MD&A · August 6, 2026
Company expects 12-month cash runway beyond August 2026
“We expect that our cash on hand and other components of working capital as of June 30, 2026, plus net cash flows from product sales will be sufficient to fund our operating expenses and capital expenditure requirements for at least 12 months beyond the filing date of this Form 10-Q notwithstanding the expiration of our credit facility on August 6, 2026.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2024-05-09 · Earnings Report — SEC 8-K filing for earnings period.
- 2024-08-08 · Earnings Report — SEC 8-K filing for earnings period.
- 2024-11-12 · Earnings Report — SEC 8-K filing for earnings period.
- 2025-02-27 · Earnings Report — SEC 8-K filing for earnings period.
- 2025-05-08 · Earnings Report — SEC 8-K filing for earnings period.
- 2025-08-07 · Earnings Report — SEC 8-K filing for earnings period.
- 2025-11-06 · Earnings Report — SEC 8-K filing for earnings period.
- 2026-02-26 · Earnings Report — SEC 8-K filing for earnings period.
Risks & what to watch (3)›
Key risks
- Large net loss — Net loss of -$96.3M as of 2026-06-30 [sec].
- Expired credit facility — Credit facility expired on August 6, 2026, reducing financial flexibility [sec_mda].
- ReNu regulatory risk — ReNu BLA not yet approved; PDUFA date is April 24, 2027 [news].
What to watch
- ReNu BLA PDUFA decision on April 24, 2027 [news].
- Next quarterly earnings report for revenue and cash trends [catalyst].
- Any updates on new credit facility or financing arrangements after August 2026 expiration [sec_mda].
Sources: Catalysts · News · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run Organogenesis Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Organogenesis Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
121
Total value held
$140.6M
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 11,616,795 | $27.5M |
| soleus capital management, l.p. | 10,085,951 | $23.9M |
| blackrock, inc. | 4,899,751 | $11.6M |
| first light asset management, llc | 3,498,533 | $8.3M |
| vanguard capital management llc | 2,900,816 | $6.9M |
| dimensional fund advisors lp | 2,891,006 | $6.9M |
| d. e. shaw & co., inc. | 2,297,974 | $5.4M |
| assenagon asset management s.a. | 1,967,952 | $4.7M |
| geode capital management, llc | 1,783,964 | $4.2M |
| deutsche bank ag\ | 1,705,681 | $4.0M |
Showing top 10 of 121 institutional holders of Organogenesis Holdings Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 19.4%
- Days to cover
- 7.5
- Shares short
- 15,855,307
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ORGO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Organogenesis Holdings Inc.?
Organogenesis Holdings Inc. (ORGO) is a regenerative medicine company focused on advanced wound care and surgical/sports medicine, with a portfolio of FDA-cleared products and a pending BLA for its ReNu knee osteoarthritis treatment.
Who is the CEO of Organogenesis Holdings Inc.?
Mr. Gary S. Gillheeney Sr. is the chief executive officer of Organogenesis Holdings Inc. (ORGO).
Where is Organogenesis Holdings Inc. headquartered?
Organogenesis Holdings Inc. (ORGO) is headquartered in Canton, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.